Literature DB >> 35118946

Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?

Sara Ibrahim Taha1, Sara Farid Samaan2, Rehab Ali Ibrahim3, Eman Mousa El-Sehsah4, Mariam Karam Youssef5.   

Abstract

BACKGROUND: Various musculoskeletal and autoimmune manifestations have been described in patients with coronavirus disease 2019 (COVID-19). 
Objectives:  This study aims to investigate the prevalence and etiology of arthritis in post-COVID Egyptian patients. 
Methods:  We included 100 post-COVID Egyptian patients who recovered 6 months ago and assessed several inflammatory and autoimmune markers. 
Results:  The prevalence of post-COVID arthritis was 37%. Ankle, knee, and wrist were the most commonly affected joints. Old age (P = 0.010), smoking (P = 0.001), and arthralgia (P = 0.049) were all linked with post-COVID arthritis. Levels of pretreatment (baseline) interleukin (IL)-6 (46.41 ± 3.67 vs. 24.03 ± 2.46; P = 0.001), as well as 6-month post-COVID C-reactive protein (CRP; 98.49 ± 67.55 vs. 54.32 ± 65.73; P = 0.002), and erythrocyte sedimentation rate (ESR; 109.08 ± 174.91 vs. 58.35 ± 37.87; P = 0.029) were significantly higher in patients with arthritis compared to those without. On the other hand, complement C3 (P = 0.558) and C4 (P = 0.192), anti-nuclear antibodies (P = 0.709), and anti-cyclic citrullinated peptides (anti-CCP; P = 0.855) did not show significant differences. Only pretreatment IL-6 level was the significant single predictor of post-COVID arthritis with an odds ratio (95% confidence interval) of 3.988 (1.460-10.892) and a P-value of 0.007.
CONCLUSION: The strong association observed with inflammatory markers (ESR and CRP) and the insignificant association with serologic markers of autoimmunity (ANA and anti-CCP) in our study support the notion that the underlying mechanism of post-COVID-19 arthritis is primarily due to the hyperinflammatory process associated with COVID-19 infection, and not the result of an autoimmune reaction. IL-6 levels before therapy can predict post-COVID arthritis allowing for early management.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 35118946      PMCID: PMC8831681          DOI: 10.1684/ecn.2021.0471

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   3.450


  33 in total

1.  Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.

Authors:  Shao Li; Ruiqin Wang; Yulong Zhang; Xuegong Zhang; A Joseph Layon; Yanda Li; Mingzhe Chen
Journal:  Am J Chin Med       Date:  2006       Impact factor: 4.667

2.  Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'

Authors:  Rashmi Roongta; Arghya Chattopadhyay; Alakendu Ghosh
Journal:  Ann Rheum Dis       Date:  2021-04-27       Impact factor: 19.103

3.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues.

Authors:  Meng-Yuan Li; Lin Li; Yue Zhang; Xiao-Sheng Wang
Journal:  Infect Dis Poverty       Date:  2020-04-28       Impact factor: 4.520

Review 4.  A Case of Systemic Lupus Erythematosus Flare Triggered by Severe Coronavirus Disease 2019.

Authors:  Sairam Raghavan; Sriram Gonakoti; Iriagbonse Rotimi Asemota; Benjamin Mba
Journal:  J Clin Rheumatol       Date:  2020-09       Impact factor: 3.517

5.  Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1.

Authors:  Nehemya Friedman; Hadar Alter; Musa Hindiyeh; Ella Mendelson; Yonat Shemer Avni; Michal Mandelboim
Journal:  Viruses       Date:  2018-09-21       Impact factor: 5.048

6.  The novel coronavirus outbreak in Wuhan, China.

Authors:  Hengbo Zhu; Li Wei; Ping Niu
Journal:  Glob Health Res Policy       Date:  2020-03-02

7.  Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.

Authors:  Kumari G Lokugamage; Adam Hage; Maren de Vries; Ana M Valero-Jimenez; Craig Schindewolf; Meike Dittmann; Ricardo Rajsbaum; Vineet D Menachery
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

Review 8.  Diagnosis and Management of Rheumatoid Arthritis: A Review.

Authors:  Daniel Aletaha; Josef S Smolen
Journal:  JAMA       Date:  2018-10-02       Impact factor: 56.272

View more
  1 in total

1.  Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors.

Authors:  Armen Yuri Gasparyan; George D Kitas
Journal:  Mediterr J Rheumatol       Date:  2022-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.